Assessment of a novel smartglass-based point-of-care fusion approach for mixed reality-assisted targeted prostate biopsy: A pilot proof-of-concept study

• Published in: Frontiers in surgery 2022-07, Vol.9, p.892170-892170
• Main Authors: Sparwasser, P., Haack, M., Frey, L., Boehm, K., Boedecker, C., Huber, T., Stroh, K., Brandt, M. P., Mager, R., Höfner, T., Tsaur, I., Haferkamp, A., Borgmann, H.
• Format: Article
• Language: English
• Subjects: augmented reality; hololens; mixed reality; prostate biopsy; prostate cancer; smartglass; Surgery
• ISSN: 2296-875X; 2296-875X
• DOI: 10.3389/fsurg.2022.892170

PurposeWhile several biopsy techniques and platforms for magnetic resonance imaging (MRI)-guided targeted biopsy of the prostate have been established, none of them has proven definite superiority. Augmented and virtual reality (mixed reality) smartglasses have emerged as an innovative technology to support image-guidance and optimize accuracy during medical interventions. We aimed to investigate the benefits of smartglasses for MRI-guided mixed reality-assisted cognitive targeted biopsy of the prostate. MethodsFor prospectively collected patients with suspect prostate PIRADS lesions, multiparametric MRI was uploaded to a smartglass (Microsoft® Hololens I), and smartglass-assisted targeted biopsy (SMART TB) of the prostate was executed by generation of a cognitive fusion technology at the point-of-care. Detection rates of prostate cancer (PCA) were compared between SMART TB and 12-core systematic biopsy. Assessment of SMART-TB was executed by the two performing surgeons based on 10 domains on a 10-point scale ranging from bad (1) to excellent (10). ResultsSMART TB and systematic biopsy of the prostate were performed for 10 patients with a total of 17 suspect PIRADS lesions (PIRADS 3, n = 6; PIRADS 4, n = 6; PIRADS 5, n = 5). PCA detection rate per core was significant (p